文献速递冠心病血脂与心血管预防

硝酸酯与PDE5抑制剂联用增加稳定冠心病患者死亡风险

Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

该研究基于瑞典登记数据,纳入2006-2013年有心肌梗死或血运重建史且6个月内两次开具硝酸酯处方的男性,比较联合使用PDE5抑制剂与单用硝酸酯的心血管结局。多变量Cox回归显示,联合治疗与全因死亡、心血管死亡、非心血管死亡、心肌梗死、心力衰竭、血运重建及MACE风险升高相关。

要点

  • 稳定冠心病硝酸酯治疗者联用PDE5i与全因死亡风险升高相关(HR 1.39)。
  • 联用PDE5i与MACE风险升高相关(HR 1.70)。
  • 处方PDE5i前需对使用硝酸酯的心血管病患者进行审慎评估。

核心结论

  • 在稳定冠心病并使用硝酸酯的男性中,联用PDE5抑制剂可能增加心血管疾病和死亡风险。

研究设计与样本

  • 基于瑞典患者登记和处方药登记,纳入2006-2013年有心肌梗死或血运重建史且6个月内两次配发硝酸酯处方的男性。
  • 暴露定义为至少两次配发任何PDE5抑制剂处方。
  • 采用多变量Cox比例风险回归估计全因、心血管和非心血管死亡、心肌梗死、心力衰竭、血运重建及MACE的风险比(HR)和95%CI。

主要发现

  • 共纳入55,777名接受硝酸酯治疗的男性和5,710名接受硝酸酯联合PDE5抑制剂治疗的男性。
  • 联合治疗与全因死亡风险升高相关(HR: 1.39; 95% CI: 1.28-1.51)。
  • 联合治疗与心血管死亡风险升高相关(HR: 1.34; 95% CI: 1.11-1.62)。
  • 联合治疗与非心血管死亡风险升高相关(HR: 1.40; 95% CI: 1.27-1.54)。
  • 联合治疗与心肌梗死(HR: 1.72; 95% CI: 1.55-1.90)、心力衰竭(HR: 1.67; 95% CI: 1.48-1.90)、血运重建(HR: 1.95; 95% CI: 1.78-2.13)及MACE(HR: 1.70; 95% CI: 1.58-1.83)风险升高相关。

临床怎么用

  • 对使用硝酸酯的稳定冠心病患者,处方PDE5抑制剂前应仔细评估风险与获益。
  • 联用PDE5抑制剂与硝酸酯时需警惕死亡和心血管事件风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phosphodiesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with lower mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI). There are conflicting results regarding the impact of PDE5i treatment on mortality in conjunction with nitrate medication. OBJECTIVES: The purpose of this study was to investigate the association between PDE5i treatment and cardiovascular outcomes in men with stable coronary artery disease treated with nitrate medication. METHODS: Using the Swedish Patient Register and the Prescribed Drug Register we included men with previous MI or revascularization in 2006-2013 who had 2 dispensed nitrate prescriptions within 6 months. Exposure was defined as at least 2 filled prescriptions of any PDE5i. We performed multivariable Cox proportional hazard regression to estimate HRs with 95% CIs for all-cause, cardiovascular, and noncardiovascular mortality, MI, heart failure, cardiac revascularization, and major cardiovascular events (MACE). RESULTS: In total, 55,777 men were treated with nitrates and 5,710 men with nitrates and a PDE5i. The combined use of PDE5i treatment with nitrates was associated with higher mortality (HR: 1.39; 95% CI: 1.28-1.51), cardiovascular mortality (HR: 1.34; 95% CI: 1.11-1.62), noncardiovascular mortality (HR: 1.40; 95% CI: 1.27-1.54), MI (HR: 1.72; 95% CI: 1.55-1.90), heart failure (HR: 1.67; 95% CI: 1.48-1.90), cardiac revascularization (HR: 1.95; 95% CI: 1.78-2.13), and MACE (HR: 1.70; 95% CI: 1.58-1.83). CONCLUSIONS: The use of a PDE5i in combination with nitrate medication in men with stable coronary artery disease may pose an increased hazard for cardiovascular morbidity and mortality. Careful patient-centered consideration before prescribing PDE5is to patients with cardiovascular disease using nitrate medication is warranted.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Trolle Lagerros Y, Grotta A, Freyland S, et al. Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors. J Am Coll Cardiol. 2024. PMID: 38233015. doi:10.1016/j.jacc.2023.10.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。